Source comparison
MK-677 Oral GH Therapy: Compound Comparison
MK-677 is frequently compared to other growth hormone secretagogues and anabolic research compounds. Understanding the distinctions is essential for protocol design. MK-677 (Ibutamoren) Ghrelin receptor agonist (GHSR1a) Oral ~24 hours Sustained GH/IGF-1 elevat
This comparison does not assign a generated winner or score.
- MK-677 is frequently compared to other growth hormone secretagogues and anabolic research compounds. Understanding the distinctions is essential for protocol design.
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist (GHSR1a)
- Oral
- ~24 hours
- Sustained GH/IGF-1 elevation, increased lean mass, orexigenic
- Best choice for long-duration oral protocols; high compliance; requires dietary control due to appetite stimulation
- CJC-1295 (with DAC)
- GHRH analog with extended half-life
- Subcutaneous injection
- 6–8 days
- Amplifies endogenous GH pulses without continuous elevation
- Superior for preserving pulsatility; requires injection; synergistic with Ipamorelin
- GHRP-2
- Growth hormone releasing peptide (GHSR agonist)
- ~30 minutes
- Acute GH pulse; strong hunger stimulation
- Shorter action than MK-677; multiple daily doses required; pronounced appetite effect limits usability
- Recombinant Human GH
- Direct GH replacement
- 2–4 hours
- Immediate pharmacological GH elevation
- Bypasses endogenous capacity; highest potency; highest cost; requires daily injection; greatest metabolic impact
- Hexarelin
- Synthetic hexapeptide GHRP
- ~70 minutes
- Potent acute GH release; cortisol/prolactin elevation
- Strong acute effect but rapid desensitization; not suitable for continuous use beyond 4–6 weeks
- Tesamorelin
- Synthetic GHRH analog
- Visceral fat reduction in HIV lipodystrophy
- FDA-approved for specific indication; modest GH response; best for targeted fat loss rather than anabolism
- MK-677 oral GH therapy occupies a unique position: it's the only orally bioavailable compound that produces sustained, multi-month GH/IGF-1 elevation without injection. For research protocols where compliance is a variable, or where daily injections introduce confounding adherence issues, MK-677 is unmatched. Its limitation is the orexigenic effect, which requires structured dietary control to prevent unintended weight gain.